Welcome!

News Feed Item

Quinnova Pharmaceuticals Announces the Launch of ECOZA™ (econazole nitrate) topical foam, 1%

CHATHAM, N.J. and JAMISON, Pa., March 18, 2014 /PRNewswire/ -- Quinnova Pharmaceuticals LLC, an affiliate of Exeltis™, today announced the launch of its recently U.S. Food and Drug Administration approved ECOZA™ (econazole nitrate) topical foam, 1%.  ECOZA™ FOAM is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.

ECOZA™ FOAM, a novel alternative for the treatment of interdigital tinea pedis (athletes foot between the toes), combines the proven antifungal efficacy of econazole nitrate with the skin-restoring properties of Proderm Technology®.  Proven to kill fungi that cause interdigital tinea pedis when applied once-daily for 4 weeks, its unique, alcohol-free foam delivery helps protect and restore skin, penetrating quickly and drying rapidly without the greasy residue that is common among other creams and gels.

"We are really excited about the launch of ECOZA™ FOAM, the first and only FDA approved prescription econazole nitrate foam in the U.S., into the almost $600M global athletes foot market. Econazole nitrate is a safe and effective topical antifungal, having been one of the most widely prescribed for the past two decades. This dosage form, using our patented Proderm Technology® that consists of a unique chemical structure that facilitates penetration of drug ingredients into the dermal layer, addresses an unmet consumer need because it is easy to apply, quickly disperses, and does not leave a residue," said Jeffrey S. Day, Executive Vice President, Dermatology of Quinnova Pharmaceuticals.  "We are pleased that ECOZA™ FOAM is now available to offer doctors and their patients a safe and effective alternative to traditional creams and gels."

Information About ECOZA™ (econazole nitrate) topical foam, 1%. 

ECOZA™ FOAM is a prescription medicine used on the skin (topical) to treat athlete's foot that is between the toes (interdigital tinea pedis) in people 12 years of age and older. ECOZA™ FOAM should be applied to cover affected areas once daily for 4 weeks. ECOZA™ FOAM is for topical use only and is not for oral, ophthalmic, or intravaginal use.

In two double-blind, parallel-group, vehicle-controlled, multicenter clinical trials, 495 subjects aged ≥12 years with a clinical diagnosis of interdigital tinea pedis and fungal culture positive for a dermatophyte at baseline received ECOZA™ FOAM (n=246) or foam vehicle (n=249).  Subjects applied ECOZA™ FOAM or foam vehicle once-daily for 4 weeks. The primary endpoint was proportion of subjects who achieved a complete cure (negative KOH, negative fungal culture, no evidence of clinical disease as indicated by complete resolution of all signs and symptoms) at 2 weeks post-treatment (Day 43).  Secondary endpoints included mycologic cure (negative KOH and negative culture) and effective treatment (mycologic cure + no or mild erythema and/or scaling and all other signs and symptoms absent).

The results from the clinical studies demonstrated that ECOZA™ FOAM exhibited superiority over foam vehicle for the primary and secondary endpoints and demonstrated potent antifungal activity against all of the pathogens evaluated with a high mycologic cure rate. The complete cure rate at Day 43 (2 weeks post-treatment) was higher in the ECOZA™ FOAM group (24.3%) than in the foam vehicle group (3.6%). In addition, higher rates of mycologic cure (67.6% vs 16.9%) and effective treatment (48.6% vs 10.8%) were observed with econazole nitrate foam 1% vs the foam vehicle. ECOZA™ FOAM was safe and well tolerated with a safety profile comparable with the foam vehicle. During clinical trials with ECOZA™ FOAM the most common adverse reactions were application site reactions, which occurred in less than 1% of subjects in both the ECOZA™ FOAM and vehicle arms. Click for full prescribing information. 

About Quinnova Pharmaceuticals

Quinnova Pharmaceuticals, LLC, is a specialty pharmaceutical company that is an affiliate of the global pharmaceutical company, Exeltis™, and was founded on innovative, patent-protected dermal delivery technologies, which are utilized to transport safe and effective pharmaceutical ingredients, through the epidermis, in unique, convenient, and cosmetically elegant formulations. Addressing a wide variety of skin conditions, Quinnova's mission is to provide superior treatment solutions and product value to clinicians and patients. For more information, visit www.quinnova.com and www.exeltis.com  

SOURCE Quinnova Pharmaceuticals, LLC

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Machine Learning helps make complex systems more efficient. By applying advanced Machine Learning techniques such as Cognitive Fingerprinting, wind project operators can utilize these tools to learn from collected data, detect regular patterns, and optimize their own operations. In his session at 18th Cloud Expo, Stuart Gillen, Director of Business Development at SparkCognition, will discuss how research has demonstrated the value of Machine Learning in delivering next generation analytics to im...
This is not a small hotel event. It is also not a big vendor party where politicians and entertainers are more important than real content. This is Cloud Expo, the world's longest-running conference and exhibition focused on Cloud Computing and all that it entails. If you want serious presentations and valuable insight about Cloud Computing for three straight days, then register now for Cloud Expo.
As you respond to increasing requests for new analytics, you need fast and flexible technology in your arsenal so that you can deploy the right workload to the right platform for the need at hand. Do you need self-service and fast time to value? Do you have data and application control and privacy needs, along with strict SLAs to meet? IBM dashDB™ is data warehouse technology powered by in-memory computing and in-database analytics that are designed for fast results, scalability and more.
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, will provide tips on how to be successful in large scale machine lear...
IoT device adoption is growing at staggering rates, and with it comes opportunity for developers to meet consumer demand for an ever more connected world. Wireless communication is the key part of the encompassing components of any IoT device. Wireless connectivity enhances the device utility at the expense of ease of use and deployment challenges. Since connectivity is fundamental for IoT device development, engineers must understand how to overcome the hurdles inherent in incorporating multipl...
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
We’ve worked with dozens of early adopters across numerous industries and will debunk common misperceptions, which starts with understanding that many of the connected products we’ll use over the next 5 years are already products, they’re just not yet connected. With an IoT product, time-in-market provides much more essential feedback than ever before. Innovation comes from what you do with the data that the connected product provides in order to enhance the customer experience and optimize busi...
The IETF draft standard for M2M certificates is a security solution specifically designed for the demanding needs of IoT/M2M applications. In his session at @ThingsExpo, Brian Romansky, VP of Strategic Technology at TrustPoint Innovation, will explain how M2M certificates can efficiently enable confidentiality, integrity, and authenticity on highly constrained devices.
The paradigm has shifted. A Gartner survey shows that 43% of organizations are using or plan to implement the Internet of Things in 2016. However, not just a handful of companies are still using the old-style ad-hoc trial-and-error ways, unaware of the critical barriers, paint points, traps, and hidden roadblocks. How can you become a winner? In his session at @ThingsExpo, Tony Shan will present a methodical approach to guide the holistic adoption and enablement of IoT implementations. This ov...
In his session at 18th Cloud Expo, Sagi Brody, Chief Technology Officer at Webair Internet Development Inc., will focus on real world deployments of DDoS mitigation strategies in every layer of the network. He will give an overview of methods to prevent these attacks and best practices on how to provide protection in complex cloud platforms. He will also outline what we have found in our experience managing and running thousands of Linux and Unix managed service platforms and what specifically c...
Artificial Intelligence has the potential to massively disrupt IoT. In his session at 18th Cloud Expo, AJ Abdallat, CEO of Beyond AI, will discuss what the five main drivers are in Artificial Intelligence that could shape the future of the Internet of Things. AJ Abdallat is CEO of Beyond AI. He has over 20 years of management experience in the fields of artificial intelligence, sensors, instruments, devices and software for telecommunications, life sciences, environmental monitoring, process...
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists will dis...
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...